These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38035921)

  • 61. Moderate alcohol consumption is not associated with subclinical cardiovascular damage but with hepatic fibrosis in non-alcoholic fatty liver disease.
    Kashiwagi K; Yamaguchi A; Shiba S; Taniki N; Inoue N; Takaishi H; Iwao Y; Kanai T
    Alcohol; 2020 Dec; 89():1-7. PubMed ID: 32738385
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Importance of cardiometabolic risk factors in the association between nonalcoholic fatty liver disease and arterial stiffness in adolescents.
    Huang RC; Beilin LJ; Ayonrinde O; Mori TA; Olynyk JK; Burrows S; Hands B; Adams LA
    Hepatology; 2013 Oct; 58(4):1306-14. PubMed ID: 23703776
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Non-alcoholic fatty liver disease (NAFLD) and significant hepatic fibrosis defined by non-invasive assessment in patients with type 2 diabetes.
    Sobhonslidsuk A; Pulsombat A; Kaewdoung P; Petraksa S
    Asian Pac J Cancer Prev; 2015; 16(5):1789-94. PubMed ID: 25773826
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Increased prevalence of cardiovascular disease in Type 1 diabetic patients with non-alcoholic fatty liver disease.
    Targher G; Pichiri I; Zoppini G; Trombetta M; Bonora E
    J Endocrinol Invest; 2012 May; 35(5):535-40. PubMed ID: 21795844
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Stenting for peripheral artery disease of the lower extremities: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(18):1-88. PubMed ID: 23074395
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Advanced glycation end product: A potential biomarker for risk stratification of non-alcoholic fatty liver disease in ELSA-Brasil study.
    Pereira ENGDS; Paula DP; de Araujo BP; da Fonseca MJM; Diniz MFHS; Daliry A; Griep RH
    World J Gastroenterol; 2021 Aug; 27(29):4913-4928. PubMed ID: 34447235
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Increased whole blood viscosity associated with arterial stiffness in patients with non-alcoholic fatty liver disease.
    Yu KJ; Zhang MJ; Li Y; Wang RT
    J Gastroenterol Hepatol; 2014 Mar; 29(3):540-4. PubMed ID: 23981121
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up.
    Fracanzani AL; Tiraboschi S; Pisano G; Consonni D; Baragetti A; Bertelli C; Norata D; Valenti L; Grigore L; Porzio M; Catapano A; Fargion S
    Atherosclerosis; 2016 Mar; 246():208-13. PubMed ID: 26803429
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Peripheral arterial disease of the lower limbs in African diabetic patients: ultrasonography and determining factors].
    Konin C; Essam N'loo AS; Adoubi A; Coulibaly I; N'guetta R; Boka B; N'djessan JJ; Koffi J; Yao H; Angoran I; Adoh M
    J Mal Vasc; 2014 Dec; 39(6):373-81. PubMed ID: 25234283
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Frequency of Nonalcoholic Fatty Liver Disease and Subclinical Atherosclerosis Among Young Mexican Americans.
    Gill C; Vatcheva KP; Pan JJ; Smulevitz B; McPherson DD; Fallon M; McCormick JB; Fisher-Hoch SP; Laing ST
    Am J Cardiol; 2017 Jun; 119(11):1717-1722. PubMed ID: 28395890
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Aortic augmentation index is independently associated with N-terminal pro B-type natriuretic peptide in patients with peripheral arterial disease.
    Shahin Y; Chetter I
    Vasc Endovascular Surg; 2012 Nov; 46(8):648-53. PubMed ID: 23047817
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Which metabolic syndrome criteria best predict non-alcoholic fatty liver disease in children?
    Atabek ME; Selver Eklioglu B; Akyürek N
    Eat Weight Disord; 2014 Dec; 19(4):495-501. PubMed ID: 24844310
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes.
    Targher G; Bertolini L; Padovani R; Rodella S; Zoppini G; Pichiri I; Sorgato C; Zenari L; Bonora E
    J Hepatol; 2010 Oct; 53(4):713-8. PubMed ID: 20619918
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The association of non-alcoholic fatty liver disease and metabolic syndrome in a Chinese population.
    Lee SW; Lee TY; Yang SS; Peng YC; Yeh HZ; Chang CS
    Hepatobiliary Pancreat Dis Int; 2017 Apr; 16(2):176-180. PubMed ID: 28381382
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Disease: Prevalence and Risk Factors.
    Principi M; Iannone A; Losurdo G; Mangia M; Shahini E; Albano F; Rizzi SF; La Fortezza RF; Lovero R; Contaldo A; Barone M; Leandro G; Ierardi E; Di Leo A
    Inflamm Bowel Dis; 2018 Jun; 24(7):1589-1596. PubMed ID: 29688336
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Association between sleep condition and arterial stiffness in Chinese adult with nonalcoholic fatty liver disease.
    Cao X; Zhou J; Yuan H; Chen Z
    J Thromb Thrombolysis; 2016 Jul; 42(1):127-34. PubMed ID: 27034174
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Clinical risk scoring for predicting non-alcoholic fatty liver disease in metabolic syndrome patients (NAFLD-MS score).
    Saokaew S; Kanchanasuwan S; Apisarnthanarak P; Charoensak A; Charatcharoenwitthaya P; Phisalprapa P; Chaiyakunapruk N
    Liver Int; 2017 Oct; 37(10):1535-1543. PubMed ID: 28294515
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The Association Between Nonalcoholic Fatty Liver Disease and Metabolic Abnormalities in The United States Population.
    Jinjuvadia R; Antaki F; Lohia P; Liangpunsakul S
    J Clin Gastroenterol; 2017 Feb; 51(2):160-166. PubMed ID: 27580477
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease.
    Semmler G; Balcar L; Wernly S; Völkerer A; Semmler L; Hauptmann L; Wernly B; Aigner E; Niederseer D; Datz C
    Front Endocrinol (Lausanne); 2023; 14():1244405. PubMed ID: 37842290
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Ambulatory arterial stiffness indices and non-alcoholic fatty liver disease in essential hypertension.
    Catena C; Bernardi S; Sabato N; Grillo A; Ermani M; Sechi LA; Fabris B; Carretta R; Fallo F
    Nutr Metab Cardiovasc Dis; 2013 Apr; 23(4):389-93. PubMed ID: 22796347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.